RECRUITING

Photodynamic Therapy (PDT) Oncology Registry

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The data elements for the PDT Registry project include virtually all the elements in the standard hospital-based cancer registry record, although in some cases at a finer level of detail. All data points should be found in the participant's medical record. The principal difference between the PDT Registry data set and that collected by the registries is the inclusion of more information specific to PDT.

Official Title

Photodynamic Therapy (PDT) Oncology Registry

Quick Facts

Study Start:2012-11
Study Completion:2024-12-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01842555

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18 years of age or older, male or female, diagnosed with cancer and is undergoing or has undergone Photodynamic Therapy (PDT).
  2. * Patients must have undergone PDT with Photofrin® at a participating institution.
  3. * Patients scheduled to undergo PDT with Photofrin®
  4. * Cancer patients receiving some or all primary care (e.g.,cancer-directed surgery, systemic therapy, radiation therapy, palliative care)in the participating institution.
  5. * Cancer patients with a history of any type of cancer who have been no evidence of disease(for five years but without a history of distant metastases or evidence of relapse if they meet the previous criteria).
  1. * Cancer patients who present to the participating institution with a diagnosis of a simultaneous second primary.
  2. * Cancer patients receiving all primary cancer care (e.g., cancer-directed surgery, chemotherapy, targeted therapy, radiation therapy, palliative care) outside of participating institution.
  3. * Patients treated with photosensitizers other than Photofrin®

Contacts and Locations

Study Contact

Patsy Skabla, PA
CONTACT
SkablaP@mlhs.org

Principal Investigator

Patrick Ross, MD, PhD
PRINCIPAL_INVESTIGATOR
Main Line Health

Study Locations (Sites)

Main Line Health, Lankenau Medical Center
Wynnewood, Pennsylvania, 19096
United States

Collaborators and Investigators

Sponsor: Main Line Health

  • Patrick Ross, MD, PhD, PRINCIPAL_INVESTIGATOR, Main Line Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2012-11
Study Completion Date2024-12-30

Study Record Updates

Study Start Date2012-11
Study Completion Date2024-12-30

Terms related to this study

Keywords Provided by Researchers

  • PDT
  • Photodynamic therapy

Additional Relevant MeSH Terms

  • Lung Cancer
  • Esophageal